Vir Biotechnology Valuation
| VIR Stock | USD 5.41 0.08 1.46% |
At this time, the company appears to be undervalued. Vir Biotechnology has a current Real Value of $8.31 per share. The regular price of the company is $5.41. Our model measures the value of Vir Biotechnology from inspecting the company fundamentals such as Current Valuation of 42.3 M, return on equity of -0.45, and Shares Owned By Insiders of 10.58 % as well as reviewing its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Vir Biotechnology's price fluctuation is slightly risky at this time. Calculation of the real value of Vir Biotechnology is based on 3 months time horizon. Increasing Vir Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Vir stock is determined by what a typical buyer is willing to pay for full or partial control of Vir Biotechnology. Since Vir Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Vir Stock. However, Vir Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.41 | Real 8.31 | Hype 5.41 | Naive 5.87 |
The intrinsic value of Vir Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vir Biotechnology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vir Biotechnology helps investors to forecast how Vir stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vir Biotechnology more accurately as focusing exclusively on Vir Biotechnology's fundamentals will not take into account other important factors: Vir Biotechnology Total Value Analysis
Vir Biotechnology is at this time forecasted to have company total value of 42.3 M with market capitalization of 758.93 M, debt of 97.89 M, and cash on hands of 2.2 B. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Vir Biotechnology fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
42.3 M | 758.93 M | 97.89 M | 2.2 B |
Vir Biotechnology Investor Information
About 79.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.73. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vir Biotechnology has Price/Earnings To Growth (PEG) ratio of 1.14. The entity recorded a loss per share of 4.23. The firm had not issued any dividends in recent years. Based on the key measurements obtained from Vir Biotechnology's financial statements, Vir Biotechnology is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.Vir Biotechnology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Vir Biotechnology has an asset utilization ratio of 5.3 percent. This connotes that the Company is making $0.053 for each dollar of assets. An increasing asset utilization means that Vir Biotechnology is more efficient with each dollar of assets it utilizes for everyday operations.Vir Biotechnology Ownership Allocation
Vir Biotechnology shows a total of 138.24 Million outstanding shares. The majority of Vir Biotechnology outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vir Biotechnology to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vir Biotechnology. Please pay attention to any change in the institutional holdings of Vir Biotechnology as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Vir Biotechnology Profitability Analysis
The company reported the last year's revenue of 74.2 M. Reported Net Loss for the year was (521.96 M) with loss before taxes, overhead, and interest of (476.86 M).About Vir Biotechnology Valuation
The stock valuation mechanism determines Vir Biotechnology's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Vir Biotechnology based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Vir Biotechnology. We calculate exposure to Vir Biotechnology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Vir Biotechnology's related companies.Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. Vir Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 444 people.
Vir Biotechnology Growth Indicators
Investing in growth stocks can be very risky. If the company such as Vir Biotechnology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 136.2 M | |
| Quarterly Earnings Growth Y O Y | 0.585 | |
| Forward Price Earnings | 4.3611 |
Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.